Refer this article to a friend :
IRIS International Receives Institutional Review Board Approval to Begin the First Stage of Its Clinical Study Using NADiA? ProsVue? for Identifying Post-Prostatectomy Patients with Low Risk of Prostate Cancer Recurrence